Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma

Article

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

Caroline Robert, MD, PhD

Caroline Robert, MD, PhD

Caroline Robert, MD, PhD

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma, according to 4-year overall survival (OS) data from KEYNOTE-001 presented at the 7th European Post-Chicago Melanoma/Skin Cancer Meeting.

At 4 years, 37.3% of patients in the overall study population were still alive and median overall survival (OS) was 23.8 months (95% CI, 20.2-30.4). In ipilimumab-naïve and ipilimumab-treated patients, median OS was 29.1 months (95% CI, 22.8-39.0) and 20.2 months (95% CI, 17.8-27.1), respectively; estimated 4-year OS rates were 41.7% and 32.7%, respectively.

OS rate at 4 years was 48% in treatment-naïve patients, and the median OS duration was 41.2 months (range, 27.2-not reached). The tail of the Kaplan-Meier OS curves implied a long-term benefit for a certain fraction of pembrolizumab-treated patients.

“After this long follow-up we show that pembrolizumab continues to demonstrate a favorable tolerability and safety profile,” Caroline Robert, MD, from the Gustave-Roussy and Paris-Sud University, said during her presentation. “The CRs [complete responses] are durable, even after this additional 6 months of follow-up. Median time to obtain complete response is a little bit more than 1 year, 91% are ongoing and the median duration of response has not been reached.”

In the phase 1b multicohort KEYNOTE-001 trial, patients received 2 mg/kg or 10 mg/kg pembrolizumab every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or investigator decision to withdraw the patient from the trial.

Median age of the patients was 61 years (range, 18-94), 62% were male, and 68% had an ECOG status of 0. The patient population had very advanced melanoma: 78% had stage M1c disease and 38% had elevated lactate dehydrogenase at baseline. Eight percent had stable brain metastases.

More than half of patients (52%) had received prior ipilimumab and 24% were treatment-naïve. Roughly a third had received 1 line of therapy, 27% had received 2 lines of therapy, and 17% had received 3 or more lines of therapy. One-third of patients (33%) had received prior chemotherapy, and 17% had previously received a BRAF inhibitor with or without a MEK inhibitor.

At the data cutoff date of September 1, 2016, the median follow-up period was 43.3 months (range, 36.0-57.1). Investigators recorded 388 deaths (59.2%), an increase of 30 patients from the 3-year analysis. Median duration of pembrolizumab treatment was 5.6 months (range, 0.03-55.2), and 238 (36.3%) patients remained on pembrolizumab for longer than 12 months. At the time of data cutoff, 104 (15.9%) patients were either still receiving pembrolizumab (n = 47) or had discontinued treatment due to experiencing complete response (n = 57).

The disease control and CR rates remained the same at 4 years when compared with the 3-year analysis, with a slight increase in the overall response rate at 4 years (34% vs 33%). Overall, 105 (16%) patients had a CR. Of those, 13% remained on pembrolizumab, 23% discontinued pembrolizumab due to adverse events (AEs), progressive disease or other reasons, and 64% stopped pembrolizumab to undergo observation.

In the complete responders who stopped pembrolizumab to undergo observation, median time to CR was 13 months (range, 3-36), and 91% of these responses were ongoing at the time of this analysis. Median CR duration has not yet been reached. Four (6%) of these patients experienced progressive disease, all of whom received further pembrolizumab treatment. Three of these patients continued to have progressive disease and one patient receiving second-line pembrolizumab had a partial response.

Compared with the previous analysis at 3 years, there was no increase in grade 3 or 4 AEs in the overall population at data cutoff (17% at both time points), nor did any additional patients discontinue treatment. There was a slight increase in the numbers of patients with hypothyroidism, hyperthyroidism and colitis at 4 years.

Long-term outcomes in patients (Pts) with advanced melanoma treated with pembrolizumab (Pembro): 4-year overall survival (OS) results from KEYNOTE-001. 7th European Post-Chicago Melanoma/Skin Cancer Meeting; June 29-30, 2017; Munich, Germany. Abstract 8.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center